Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum

Sato,Takamichi; Okazaki,Manami; Sano,Junko; Kato,Chihiro; Shimizu,Kazuhisa; Kitagawa,Masayuki

doi:10.3892/br.2021.1411

Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum

Authors:
- Takamichi Sato
- Manami Okazaki
- Junko Sano
- Chihiro Kato
- Kazuhisa Shimizu
- Masayuki Kitagawa
View Affiliations

Affiliations: Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd., Tokyo 115‑0042, Japan
Published online on: February 11, 2021 https://doi.org/10.3892/br.2021.1411
Article Number: 35

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nanoparticle albumin‑bound (nab)‑paclitaxel is a 130‑nm formulation containing human serum albumin (HSA). The clinical efficacy of this formulation is considered to depend on its affinity for HSA. The high pressure employed during the manufacture of nab‑paclitaxel HSA (nab HSA) may influence its conformation and/or oligomerization, and ultimately its affinity for HSA. Therefore, studies are required to evaluate whether the affinity of paclitaxel for nab HSA is similar to that of generic HSA (control HSA). In the present study, nab HSA was isolated from nab‑paclitaxel by gel filtration, and the binding affinities (K_Ds) were determined by surface plasmon resonance. Furthermore, the affinity of docetaxel for nab HSA and control HSA was measured, as their binding sites are similar. Paclitaxel showed KDs of 8.93±8.60 and 7.39±5.81 µM for nab HSA and control HSA, respectively, whereas the corresponding K_Ds for docetaxel were 44.3±9.50 and 55.9±2.28 µM, respectively. This suggests that the paclitaxel binding site was not modified during the nab‑paclitaxel manufacturing process. Additionally, nab HSA likely does not affect paclitaxel and blood HSA binding, as evidenced by the similar affinities of paclitaxel and docetaxel for nab HSA and control HSA. In conclusion, the binding affinities of paclitaxel and docetaxel for nab HSA and control HSA were found to be comparable. Additionally, the manufacturing process did not influence the paclitaxel binding affinity for nab HSA. These results also suggest that nab HSA may not affect the clinical effectiveness of nab‑paclitaxel.

View Figures

View References

1	Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 12:1317–1324. 2006.PubMed/NCBI View Article : Google Scholar
2	Yardley DA: nab-Paclitaxel mechanisms of action and delivery. J Control Release. 170:365–372. 2013.PubMed/NCBI View Article : Google Scholar
3	Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, et al: Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol. 76:699–712. 2015.PubMed/NCBI View Article : Google Scholar
4	Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, et al: German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Investigators: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016.PubMed/NCBI View Article : Google Scholar
5	Merlot AM, Kalinowski DS and Richardson DR: Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 5(299)2014.PubMed/NCBI View Article : Google Scholar
6	Sollenne NP, Wu HL and Means GE: Disruption of the tryptophan binding site in the human serum albumin dimer. Arch Biochem Biophys. 207:264–269. 1981.PubMed/NCBI View Article : Google Scholar
7	Nakano NI, Shimamori Y and Yamaguchi S: Binding capacities of human serum albumin monomer and dimer by continuous frontal affinity chromatography. J Chromatogr A. 237:225–232. 1982.PubMed/NCBI View Article : Google Scholar
8	Matsushita S, Chuang VT, Kanazawa M, Tanase S, Kawai K, Maruyama T, Suenaga A and Otagiri M: Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin. Pharm Res. 23:882–891. 2006.PubMed/NCBI View Article : Google Scholar
9	Paal K, Shkarupin A and Beckford L: Paclitaxel binding to human serum albumin - automated docking studies. Bioorg Med Chem. 15:1323–1329. 2007.PubMed/NCBI View Article : Google Scholar
10	Paál K, Müller J and Hegedûs L: High affinity binding of paclitaxel to human serum albumin. Eur J Biochem. 268:2187–2191. 2001.PubMed/NCBI View Article : Google Scholar
11	Purcell M, Neault JF and Tajmir-Riahi HA: Interaction of taxol with human serum albumin. Biochim Biophys Acta. 1478:61–68. 2000.PubMed/NCBI View Article : Google Scholar
12	Amani N, Saberi MR and Chamani JK: Investigation by fluorescence spectroscopy, resonance rayleigh scattering and zeta potential approaches of the separate and simultaneous binding effect of Paclitaxel and estradiol with human serum albumin. Protein Pept Lett. 18:935–951. 2011.PubMed/NCBI View Article : Google Scholar
13	Atmeh RF and Shabsoug B: Detection and semiquantitation of albumin forms in fresh human plasma separated on gradient polyacrylamide gel by means of electroblotting on agarose gel matrix. Electrophoresis. 18:2055–2058. 1997.PubMed/NCBI View Article : Google Scholar
14	Cimitan S, Lindgren MT, Bertucci C and Danielson UH: Early absorption and distribution analysis of antitumor and anti-AIDS drugs: Lipid membrane and plasma protein interactions. J Med Chem. 48:3536–3546. 2005.PubMed/NCBI View Article : Google Scholar
15	Paal K and Shkarupin A: Paclitaxel binding to the fatty acid-induced conformation of human serum albumin - automated docking studies. Bioorg Med Chem. 15:7568–7575. 2007.PubMed/NCBI View Article : Google Scholar
16	Gordon EM, Chua-Alcala VS, Kim K, Baby R, Angel N, Quon D, Wong S and Chawla SP: A phase I/II investigation of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: Preliminary efficacy and safety results. J Clin Oncol. 37 (Suppl 15)(11057)2019.
17	Khodaei A, Bolandnazar S, Valizadeh H, Hasani L and Zakeri-Milani P: Interactions between sirolimus and anti-inflammatory drugs: Competitive binding for human serum albumin. Adv Pharm Bull. 6:227–233. 2016.PubMed/NCBI View Article : Google Scholar